Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 9Squamous Cell Carcinoma of Head and Neck 4Nasopharyngeal Carcinoma 4Esophageal Squamous Cell Carcinoma 4Carcinoma, Non-Small-Cell Lung 4Triple Negative Breast Neoplasms 3Stomach Neoplasms 3Esophageal Neoplasms 3Uterine Cervical Neoplasms 2Pancreatic Neoplasms 2Locally Advanced Rectal Cancer 2Colonic Neoplasms 2Cervical Cancer Metastatic 2Breast Neoplasms 2Adenocarcinoma 2Turcot syndrome 1Salivary Gland Neoplasms 1Recurrence 1Rectal Cancer Patients 1Non-squamous Non-small-cell Lung Cancer 1Mouth Neoplasms 1Liver Neoplasms 1Leukemia, Myeloid, Acute 1Laryngeal Neoplasms 1Gestational Trophoblastic Disease 1Esophageal Squamour Cell Cancer 1Endometrioid Endometrial Cancer 1Colorectal Neoplasms 1Biliary Tract Neoplasms 1Advanced Primary Liver Cancer 1

Interventions

irinotecan sucrosofate 1camrelizumab 1Radiotherapy 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Rectal Cancer Patients × camrelizumab × 1 year × Clear all
NCT07521605 2026-04-13

Short-Course Radiotherapy, Nal-IRI, Capecitabine, and Camrelizumab for Locally Advanced MSS Rectal Cancer

Guangdong Provincial People's Hospital

Phase 2 Not yet recruiting
44 enrolled
Gastrointestinal

Rectal Cancer Patients

Data powered by HemOnc (CC BY 4.0) Colophon âš¡